Are you interested in hearing about the PROMISE study, which screened over 30,000 individuals for monoclonal gammopathies?🩸

Make sure you don't forget to watch our interview from #ASH25 with @SabineWaelAllam of @DanaFarber:

🎥 ➡️

#SmolderingMyeloma… https://twitter.com/i/web/status/2016209786405065135

The PROMISE study: screening over 30,000 individuals for monoclonal gammopathies

In this interview, Sabine Allam, MD, Dana Farber Cancer Institute, Boston, MA, discusses the results of the PROMISE ...

ow.ly

It was great to speak with @jeff_sharman of @WVCancer recently to hear the interim results from a cohort of the MorningSun study, which evaluated fixed-duration SC mosunetuzumab in older/unfit patients with previously untreated #DLBCL.

Watch here: 👉 … https://twitter.com/i/web/status/2016073790870938001

Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial

Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR,...

ow.ly

Is there a way to predict and prevent therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation?💭

We spoke with @DrPinkalDesai of @WeillCornell at #ASH25 to gain valuable insight into this – watch the interview here:

👉 👈… https://twitter.com/i/web/status/2015847451836416182

Predicting and preventing therapy-related myeloid neoplasms

Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predict...

ow.ly

In an interview from #ASH25, Heather Landau (@MSKCancerCenter) presents data from the first 20 pts treated in the NEXICART-2 trial, a Phase I/II dose escalation/expansion study of the BCMA-directed #CARTCell therapy NXC-201 in R/R AL #amyloidosis.

Watch now: 👉…

Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis

Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses data from the first 20 patients ...

twitter.com